DIAGNOS Announces HIPAA Compliance for the US market

DIAGNOS Inc. (“DIAGNOS”, “the Corporation” or “we”) (TSX Venture: ADK) (OTCQB: DGNOD), a leader in early detection of critical health issues through the use of its FL

AI

RE platform based on Artificial Intelligence (

AI

), announces today that its quality management system now fully complies with the requirements of the Health Insurance Portability and Accountability Act (“HIPAA”).

HIPAA sets the standard for sensitive patient data protection. DIAGNOS has put in place the necessary physical network, and process security measures to ensure HIPAA Compliance. Covered entities (anyone providing treatment, payment, and operations in healthcare) and business associates (anyone who has access to patient information and provides support in treatment, payment, or operations) must meet HIPAA Compliance.

In the coming months, DIAGNOS will be addressing the US market with a new release of its early detection algorithms and will be seeking an updated Food and Drug Administration clearance on them.  “As we reinforce our CARA solution with this most powerful release, we are making sure that we are compliant with all regulatory processes for a full deployment across the USA in the coming year,” said Mr. André Larente, President of DIAGNOS.

About DIAGNOSDIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.

Additional information is available at www.diagnos.com and www.sedar.com

For further information, please contact:

Mr. André Larente, PresidentDIAGNOS IncTel: 450-678-8882 ext. [e-mail]

This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements.DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.